Stuart E Lind
Physician at Dorado Pl, Englewood, CO
License number
Colorado 44473
Issued Date
Mar 31, 2006
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
6605 E Dorado Pl, Englewood, CO 80111
Personal information
See more information about Stuart E Lind at radaris.comName
Address
Phone
6605 Dorado Pl, Englewood, CO 80111
Denver, CO
Organization information
See more information about Stuart E Lind at bizstanding.comStuart E Lind MD
6605 Dorado Pl, Englewood, CO 80111
Industry:
Medical Doctor's Office
Principal:
Stuart Lind (Principal)
Professional information
See more information about Stuart E Lind at trustoria.com
Conjugate For The Specific Targeting Of Anticancer Agents To Tumor Cells Or Tumor Vasculature And Production Thereof
Conjugate For The Specific Targeting Of Anticancer Agents To Tumor Cells Or Tumor Vasculature And Production Thereof
US Patent:
2009030, Dec 10, 2009
Filed:
Jul 13, 2009
Appl. No.:
12/502011
Inventors:
Roger G. Harrison - Norman OK, US
J. Thomas Pento - Norman OK, US
Stuart E. Lind - Greenwood Village CO, US
J. Thomas Pento - Norman OK, US
Stuart E. Lind - Greenwood Village CO, US
International Classification:
A61K 38/51, A61P 35/00, C12N 5/06
US Classification:
424 945, 435375
Abstract:
A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.
Conjugate For The Specific Targeting Of Anticancer Agents To Tumor Cells Or Tumor Vasculature And Production Thereof
Conjugate For The Specific Targeting Of Anticancer Agents To Tumor Cells Or Tumor Vasculature And Production Thereof
US Patent:
2007020, Sep 6, 2007
Filed:
Feb 28, 2007
Appl. No.:
11/712140
Inventors:
Roger Harrison - Norman OK, US
J. Pento - Norman OK, US
Stuart Lind - Greenwood Village CO, US
J. Pento - Norman OK, US
Stuart Lind - Greenwood Village CO, US
International Classification:
A61K 39/395, A61K 38/48
US Classification:
424155100, 424094630, 424178100
Abstract:
A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.